In a forward-looking report entitled, "The Future of Self-Monitored Blood Glucose: Mean Blood Glucose Versus Glycosylated Hemoglobin," Roger Mazze, PhD, from the University of Minnesota Medical School, Minneapolis, emphasizes the importance of SMBG in monitoring diurnal glucose patterns, rather than relying solely on HbA1C or mean glucose levels, which can be misleading indicators of therapeutic efficacy.
Diabetes Technology & Therapeutics is a peer-reviewed journal published bimonthly that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed online at http://www.liebertpub.com/dia
Mary Ann Liebert, Inc., is a privately held, fully integrated media
company known for establishing authoritative peer-reviewed journals in many
promising areas of science and biomedical research, including, Thyroid,
Metabolic Syndrome and Related Disorders, Obesity Management, and Journal
of Aerosol Medicine and Pulmonary Drug Delivery. Its biotechnology trade
magazine, Genetic Engineering & Biotechnology News (GEN), was the first in
its field and is today the industry's most widely read pu
'/>"/>
| SOURCE Diabetes Technology & Therapeutics Copyright©2008 PR Newswire. All rights reserved |